Show simple item record

dc.contributor.authorZheng, Yue
dc.contributor.authorLarragoite, Erin T
dc.contributor.authorWilliams, Elizabeth S C P
dc.contributor.authorLama, Juan
dc.contributor.authorCisneros, Isabel
dc.contributor.authorDelgado, Julio C
dc.contributor.authorSlev, Patricia
dc.contributor.authorRychert, Jenna
dc.contributor.authorInnis, Emily A
dc.contributor.authorCoiras, Mayte 
dc.contributor.authorRondina, Matthew T
dc.contributor.authorSpivak, Adam M
dc.contributor.authorPlanelles, Vicente
dc.identifier.citationVirol J. 2021 Jan 4;18(1):1.es_ES
dc.description.abstractBackground: Virus neutralization by antibodies is an important prognostic factor in many viral diseases. To easily and rapidly measure titers of neutralizing antibodies in serum or plasma, we developed pseudovirion particles composed of the spike glycoprotein of SARS-CoV-2 incorporated onto murine leukemia virus capsids and a modifed minimal murine leukemia virus genome encoding frefy luciferase. This assay design is intended for use in laboratories with biocontainment level 2 and therefore circumvents the need for the biocontainment level 3 that would be required for replication-competent SARS-CoV-2 virus. To validate the pseudovirion assay, we set up comparisons with other available antibody tests including those from Abbott, Euroimmun and Siemens, using archived, known samples. Results: 11 out of 12 SARS-CoV-2-infected patient serum samples showed neutralizing activity against SARS-CoV2-spike pseudotyped MLV viruses, with neutralizing titers-50 (NT50) that ranged from 1:25 to 1:1,417. Five historical samples from patients hospitalized for severe infuenza infection in 2016 tested negative in the neutralization assay (NT50<25). Three serum samples with high neutralizing activity against SARS-CoV-2/MLV pseudoviruses showed no detectable neutralizing activity (NT50<25) against SARS-CoV-1/MLV pseudovirions. We also compared the semiquantitative Siemens SARS-CoV-2 IgG test, which measures binding of IgG to recombinantly expressed receptor binding domain of SARS-CoV-2 spike glycoprotein with the neutralization titers obtained in the pseudovirion assay and the results show high concordance between the two tests (R2=0.9344). Conclusions: SARS-CoV-2 spike/MLV pseudovirions provide a practical means of assessing neutralizing activity of antibodies in serum or plasma from infected patients under laboratory conditions consistent with biocontainment level 2. This assay ofers promise also in evaluating immunogenicity of spike glycoprotein-based candidate vaccines in the near future.es_ES
dc.description.sponsorshipThis research was supported by a seed grant from the University of Utah Vice President for 151 Research and the Immunology, Inflammation, and Infectious Disease Initiative. V.P. and M.C. were 152 supported by NIH grant AI143567-01es_ES
dc.publisherBioMed Central (BMC) es_ES
dc.subjectNeutralization assayes_ES
dc.subjectPseudotyped viruses_ES
dc.subjectMurine leukemia viruses_ES
dc.titleNeutralization Assay with SARS-CoV-1 and SARS-CoV-2 Spike Pseudotyped Murine Leukemia Virionses_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.contributor.funderUniversity of Utah (Estados Unidos)es_ES
dc.contributor.funderNational Institutes of Health (Estados Unidos)es_ES
dc.identifier.journalVirology Journales_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.rights.accessRightsopen accesses_ES

Files in this item

Acceso Abierto

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional